Restoring Hormone Balance: A Patient-Centered Guide
Restoring Hormone Balance: A Patient-Centered Guide
Share
Table of Contents
Restoring Hormone Balance With an Integrative Approach
Abstract
In this educational post, I walk you through a comprehensive, patient-centered approach to menstrual health, iron deficiency, polycystic ovary syndrome (PCOS), post-bariatric care, and testosterone therapy. Using current research and my clinical experience, I explain how cyclic progesterone, iron replenishment, thyroid health, estrogen management, SHBG levels, and careful androgen dosing work in the body. I also describe how integrative chiropractic care fits into this continuum: modulating autonomic tone, improving microvascular perfusion, reducing inflammatory burden, and enhancing tissue-level hormone signaling, all in synergy with pharmacologic therapies. My goal is to make these concepts easy to follow while honoring their complexity, so you can apply them safely and effectively.
Introduction: My Integrative Framework for Hormone and Menstrual Health
As a clinician working at the intersection of functional medicine, primary care, and chiropractic, I see a consistent pattern: patients do best when we integrate hormonal physiology, micronutrient status, metabolic fitness, and musculoskeletal-autonomic regulation. In this post, I reword and expand on common clinical themes—from iron deficiency and cyclic progesterone to testosterone pellets and SHBG—and present them through the lens of systems physiology. I include my observations from daily practice and research curation, and explain how integrative chiropractic care enhances outcomes alongside endocrine therapies.
Key themes you will learn:
Why iron deficiency and thyroid status shape uterine bleeding and energy
How cyclic progesterone reduces heavy bleeding and stabilizes cycles
The rationale for testosterone dosing is based on absorption, distribution, and renal excretion
How SHBG impairs symptom response and how to navigate contraception in perimenopause
What to consider in post-bariatric patients with malabsorption and microbiome shifts
When to use nutraceuticals like DIM and when to reassess dosing rather than block estrogen
Where integrative chiropractic care fits: autonomic balance, perfusion, pain modulation, and exercise readiness
Iron Deficiency, Thyroid Function, and Menstrual Bleeding: The Foundational Physiologic Loop
When a woman presents with heavy or prolonged bleeding, the first move is to put the right team in the room—medical, nutritional, and integrative clinicians—to assess the foundational loops. Iron deficiency and thyroid dysfunction frequently co-occur with abnormal uterine bleeding.
Iron deficiency physiology:
Ironis essential for hemoglobin synthesis and oxygen transport. Low ferritin and transferrin saturation impede oxygen delivery to endometrial tissue and impair mitochondrial function, driving fatigue and amplifying bleeding-related symptoms (Pasricha et al., 2021).
Iron status also influences coagulation and platelet function; deficiency can contribute to dysfunctional hemostasis in the endometrium (Goddard et al., 2011).
Clinically, I find that women with ferritin levels below 30–50 ng/mL and transferrin saturation under 20% are more likely to have fatigue, exertional tachycardia, and heavier menses. Repleting iron normalizes energy and bleeding curves.
Thyroid function and endometrial dynamics:
Hypothyroidism is linked to menorrhagia via altered estrogen metabolism, increased TRH-induced prolactin (affecting gonadotropins), and changes in coagulation factors (Krassas et al., 2010).
Normalizing TSH, free T4, and free T3 improves endometrial receptivity and cycle regularity.
Practical steps:
Assess CBC, ferritin, iron panel, TSH, free T4/T3, and CRP.
Initiate oral iron (e.g., ferrous bisglycinate 25–50 mg elemental iron daily) or IV iron if malabsorption or intolerance is present, and correct thyroid abnormalities according to evidence-based protocols (Cappellini et al., 2020; Krassas et al., 2010).
Combine with cyclic progesterone to stabilize bleeding while the iron-thyroid axis is addressed.
Why Cyclic Progesterone Helps Heavy Bleeding
Progesterone counterbalances estrogen-driven endometrial proliferation. In luteal-phase physiology, progesterone induces secretory transformation and promotes orderly endometrial shedding.
Modulates myometrial contractility and prostaglandins, easing dysmenorrhea.
Clinical use:
For heavy bleeding, I often start with cyclic oral micronized progesterone (e.g., 200 mg nightly days 14–28) for several cycles, then reassess flow and ferritin.
In higher bleeding burden, extending progesterone cycles or increasing dose (e.g., 200 mg for 10–14 days per cycle, then taper) can stabilize the endometrium while iron repletion occurs.
Why this works:
It addresses the source of bleeding (endometrial stability) while iron replaces losses and thyroid normalizes systemic metabolism.
PCOS: Metabolic and Hormonal Nuances
PCOS is characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance, with elevated LH:FSH ratios in many patients. Treatment must respect cardiometabolic risk and fertility goals.
Physiology:
Insulin resistance increases ovarian androgen production and decreases SHBG, raising free testosterone and exacerbating symptoms (Azziz et al., 2016).
Chronic low-grade inflammation and adiposity contribute to dysregulated ovulation and endometrial health.
Interventions:
Lifestyle: structured exercise, sleep optimization, and low-glycemic nutrition improve insulin sensitivity and SHBG.
Cyclic progesterone can regulate bleeding and protect the endometrium in anovulatory cycles.
Metformin and incretin-based therapies can be used in appropriate patients to restore ovulation and metabolic health (Legro et al., 2013).
My observation:
In PCOS, responding to bleeding with progesterone cycling while normalizing iron and thyroid often accelerates symptomatic relief. I also emphasize autonomic and musculoskeletal support through integrative chiropractic care to help patients sustain exercise and reduce stress-related cortisol surges.
Post-Gastric Bypass: Malabsorption, Microbiome, and Hormone Therapy
After bariatric procedures, patients face unique absorption challenges and shifts in the microbiome.
Nutritional physiology:
Reduced gastric volume and altered small bowel transit impair absorption of iron, B12, fat-soluble vitamins, and some pharmaceuticals (Mechanick et al., 2020).
Microbiome changes influence estrogen metabolism via the estrobolome, affecting systemic estrogen signaling.
Practical approach:
Use bioavailable forms and consider parenteral iron or B12 if deficits persist.
Employ targeted probiotics to improve gut barrier integrity and help restore metabolite balance (Sánchez-Tapia et al., 2020). While probiotics are not a panacea, certain strains support post-bariatric gut health.
Hormone therapy considerations:
In malabsorption, transdermal or pellet delivery of hormones may bypass GI variability.
Monitor levels and symptoms closely—absorption can be erratic early post-op.
My clinical stance:
I treat core physiology the same—correct deficiencies, stabilize bleeding with progesterone when indicated, and titrate hormone therapy with careful lab and symptom follow-up. If absorption appears unreliable, I switch route or consider parenteral repletion.
Androgen Therapy: Absorption, Distribution, and Renal Excretion
Successful testosterone therapy hinges on three pharmacokinetic pillars—absorption, distribution, and excretion.
Absorption:
Subcutaneous pellets and transdermal gels rely on capillary perfusion of subcutaneous tissue. Higher cardiac output and regional blood flow enhance early release kinetics.
Exercise improves perfusion, often yielding faster attainment of steady-state levels.
Distribution:
Testosterone distributes across the total body water and adipose compartments. Higher BMI and adiposity can dilute effective concentrations, altering clinical response despite equal dosing (Saad et al., 2017).
Excretion:
Testosterone and metabolites are cleared via hepatic metabolism and renal excretion of conjugates. In older patients or those with reduced renal function, the effective half-life can be prolonged, causing lower doses to last longer (Corona et al., 2014).
Clinical implications:
Patients who lose 20% of body fat often require lower maintenance dosing, as distribution volume narrows.
In octogenarian men, I often use lower pellet loads; kinetics stretch out, sometimes giving 6–9 months of symptom relief on modest doses.
Why avoid reflex estrogen blockers:
Breast tenderness in men typically occurs during the initial rapid rise in testosterone, not in stable maintenance. If tenderness persists, first evaluate dose and timing rather than immediately adding aromatase inhibitors.
DIM (diindolylmethane) may support estrogen metabolism in select cases, but I prioritize dose calibration and improvements in body composition over blocking estradiol, given estradiol’s role in bone, brain, and cardiovascular health (Finkelstein et al., 2013).
SHBG, Contraception, and Female Androgen Response
Sex hormone–binding globulin (SHBG) regulates the availability of free hormones. Elevated SHBG can blunt the response to testosterone therapy in women.
Physiology:
SHBG binds testosterone and estradiol; only free and albumin-bound fractions are bioactive. Combined oral contraceptives often increase SHBG, reducing free testosterone (Zimmerman et al., 2014).
Clinical scenario:
A 45-year-old woman on combined contraceptives may have SHBG >100 nmol/L, rendering standard testosterone doses ineffective. Clinically, she “doesn’t feel a smidge” of benefit until total T is very high—an approach I avoid for safety reasons and because it’s unnecessary.
Strategy:
If contraception is required, consider non-estrogen options:
Levonorgestrel IUD for local progestin effect without raising SHBG substantially
Copper IUD if appropriate
By reducing SHBG’s impact, a physiologic testosterone dose can produce meaningful symptom relief.
Risk-benefit perspective:
In women without pregnancy need (post-tubal ligation or with IUD), I avoid combined oral contraceptives for PMS or heavy menses when safer options—cyclic progesterone, IUDs, NSAIDs, and tranexamic acid—can manage symptoms without elevating DVT risk (Lidegaard et al., 2012; Marjoribanks et al., 2016).
Integrative Chiropractic Care: Autonomic Modulation and Tissue-Level Hormone Signaling
How does integrative chiropractic care fit into endocrine therapy? Through autonomic regulation, perfusion, and pain modulation, it improves the terrain in which hormones act.
Autonomic tone and microcirculation:
Chronic pain elevates sympathetic output, constricting peripheral vessels and impairing capillary exchange—precisely where transdermal and pellet hormones are absorbed.
Evidence suggests that manual therapy can lower sympathetic arousal, improve HRV, and normalize baroreflex sensitivity, indirectly enhancing tissue perfusion (Pickar & Bolton, 2012).
Musculoskeletal integration:
Pelvic and lumbar dysfunction amplify pelvic floor tension and myofascial pain, worsening menstrual symptoms. Targeted adjustments, soft-tissue mobilization, and neuromuscular reeducation decrease nociceptive input and reduce prostaglandin-driven cramping.
Better biomechanics increase exercise adherence, improving insulin sensitivity and lowering androgen excess in PCOS.
Inflammation and recovery:
Low-grade inflammation impairs hormone receptor signaling. Chiropractic interventions, coupled with anti-inflammatory nutrition and sleep hygiene, lower systemic inflammatory markers, thereby improving subjective and objective responses to hormone therapy (Teodorczyk-Injeyan et al., 2018).
My practice observations:
As documented on my platforms, I routinely combine endocrine regimens with spine-pelvis care and rehabilitation pathways so patients tolerate activity, stabilize cycles, and maintain iron repletion more easily.
Practical Dosing Logic for Testosterone Therapy
In individuals, dosing logic should track the pharmacokinetic triad and clinical goals.
Starting scenarios:
Men with low baseline T may experience transient breast tenderness during the first high rise. I preempt this by careful titration, advising on timing and avoiding unnecessary aromatase blockade. If tenderness occurs, I reassess the dose rather than default to inhibitors.
Older adults with slower clearance need lower loads and longer intervals.
Weight changes:
After significant weight loss, changes in distribution reduce the required dose. This is why a patient moving from 250 to 190 lb often reaches target levels with less—not more—testosterone.
Monitoring:
Track symptoms, free and total testosterone, estradiol, hematocrit, PSA (men), lipids, liver enzymes, and renal function.
Avoid hemoglobin overshoot by adhering to conservative titration and addressing sleep apnea, hydration, and altitude exposure (Coviello et al., 2008).
Why this approach:
Optimizing the dose based on physiology avoids roller-coaster symptoms and reduces unnecessary polypharmacy. It respects estradiol’s protective roles while delivering androgenic benefits for lean mass, libido, mood, and bone health.
Clarifying Myths: ED, Testosterone, and Arrhythmia
Patients and gym peers sometimes conflate erectile dysfunction (ED), testosterone therapy, and cardiac arrhythmias.
ED is often vascular or neurogenic rather than purely hormonal. Normalizing testosterone may improve libido and erectile quality in hypogonadal men, but ED commonly reflects endothelial health, PDE5 responsiveness, and autonomic balance (Corona et al., 2014).
Regarding arrhythmia or cardioversion outcomes, some observational data suggest better outcomes in eugonadal men, but arrhythmia pathways are distinct from androgen status. Correct deficiencies and monitor, but do not mechanistically conflate ED and arrhythmia risk.
Premenopausal Versus Menopausal Progestogens: Why the Choice Changes
Why do we use progestins (synthetic progestogens) in premenopausal contraception, yet favor micronized progesterone in perimenopause/menopause?
Different clinical aims:
Contraceptive progestins aim to suppress ovulation and thicken cervical mucus. Their pharmacology prioritizes reliable pregnancy prevention.
Menopausal therapy aims to treat symptoms (vasomotor instability, sleep disturbance, mood) and protect the endometrium when using estradiol.
Physiology and safety:
Micronized progesterone shows favorable effects on sleep, mood, and lipids, and may have a more favorable breast and cardiovascular risk profile than several synthetic progestins when combined with transdermal estradiol (Stute et al., 2016).
Thus, I choose the molecule based on intent: contraception versus symptom therapy and tissue protection.
Risk of DVT, Stroke, and Contraceptive Strategy in Midlife
Risk stratification matters. In women 40–50 without a need for pregnancy prevention (due to IUD or tubal ligation), the risk-benefit ratio often favors avoiding combined oral contraceptives for symptom control.
Evidence:
Combined oral contraceptives modestly increase venous thromboembolism (VTE) risk, especially with certain progestins and higher estrogen doses (Lidegaard et al., 2012).
For heavy menses, consider levonorgestrel IUD, cyclic progesterone, tranexamic acid, and lifestyle-metabolic support—effective without the same VTE profile.
Clinical pearl:
Ask: Is she taking pills for birth control or symptom management? If contraception is unnecessary, switch to lower-risk modalities and treat the underlying physiology.
Environmental Exposures, SHBG, and “Lowering Supplements”
Patients often ask about environmental exposures or supplements marketed to “lower SHBG.”
Reality check:
Many supplements change SHBG by 10–15%, which rarely translates into meaningful symptom change if overall physiology is not addressed (diet, insulin sensitivity, sleep, inflammation).
Focus on metabolic health, protein adequacy, resistance training, and thyroid optimization—these have larger effects on androgen bioavailability and symptom relief.
Labs: CBC, ferritin, iron panel, TSH, free T4/T3, estradiol/progesterone (cycle-timed if premenopausal), total/free testosterone, SHBG, lipids, CRP, A1C, vitamin D, B12, folate, and renal panel
Immediate Stabilization
Cyclic progesterone if heavy bleeding
Iron repletion and thyroid normalization if deficient
Pelvic-lumbar chiropractic assessment and targeted manual therapy to reduce pain and autonomic arousal
Individualized Hormone Strategy
PCOS: insulin sensitivity first, progesterone protection, and careful androgen considerations
Midlife women with high SHBG: reconsider estrogen-containing contraception; use IUDs or micronized progesterone strategies
Men: titrate testosterone with perfusion and clearance in mind; avoid reflex aromatase blockade
Lifestyle and Integrative Reinforcements
Structured exercise progression supported by musculoskeletal care
Sleep interventions to normalize cortisol rhythm
Anti-inflammatory nutrition and gut support, particularly post-bariatric
Monitoring and Iteration
Symptom scales, lab follow-up, dose adjustments
Reinforce rehabilitation and autonomic balance to sustain gains
What Success Looks Like
Bleeding normalizes, and ferritin rises to ?50–70 ng/mL
Energy, sleep, mood, and exercise capacity improve
PCOS patients regain cycle regularity, and metabolic markers improve
Testosterone recipients achieve stable symptom relief without excessive estradiol blockade or hematocrit elevation
Patients report reduced pain, better stress tolerance, and consistency in health behaviors—often aided by integrative chiropractic care
Closing Thoughts
Precision hormone care lives at the intersection of endocrinology, metabolism, and neuro-musculoskeletal integration. When we stabilize iron and thyroid, leverage progesterone intelligently, respect SHBG dynamics, and dose androgens according to physiologic kinetics, patients thrive. Integrative chiropractic care strengthens the autonomic and biomechanical foundations that enable these therapies to work more effectively. My commitment is to pursue excellence in every detail—from testing and dosing to recovery and resilience—so each patient experiences consistent, durable improvements.
References
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., & Lizneva, D. (2016). Polycystic ovary syndrome. https://doi.org/10.1038/nrdp.2016.4
Cappellini, M. D., Musallam, K. M., Taher, A. T. (2020). Iron deficiency anemia revisited. https://doi.org/10.1038/s41430-020-00740-7
Corona, G., Rastrelli, G., Maggi, M. (2014). Testosterone replacement therapy: What we know and what we don’t. https://doi.org/10.1111/andr.12056
Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., & Bhasin, S. (2008). Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. https://doi.org/10.1210/jc.2007-1692
Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., Pallais, J. C., Yu, E. W., Borges, L. F., … Bhasin, S. (2013). Estrogen vs testosterone in male sexual function. https://doi.org/10.1056/NEJMoa1206179
Goddard, A. F., James, M. W., McIntyre, A. S., & Scott, B. B. (2011). Guidelines for the management of iron deficiency anaemia. https://doi.org/10.1136/gut.2010.228874
Krassas, G. E., Poppe, K., & Glinoer, D. (2010). Thyroid function and human reproductive health. https://doi.org/10.1080/09513590903114118
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013). Diagnosis and treatment of PCOS. https://doi.org/10.1210/jc.2013-2350
Lidegaard, Ø., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Løkkegaard, E. (2012). Risk of venous thromboembolism from contraceptives. https://doi.org/10.1136/bmj.e4544
Maybin, J. A., & Critchley, H. O. D. (2015). Menstrual physiology and heavy menstrual bleeding. https://doi.org/10.1038/nrgastro.2015.164
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Morton, J. M., … Huria, T. (2020). Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures. https://doi.org/10.1007/s11695-020-04432-3
Pickar, J. G., & Bolton, P. S. (2012). Spinal manipulation and somatosensory control of sympathetic activity. https://doi.org/10.1177/1756283X12452335
Saad, F., Aversa, A., Isidori, A. M., & Gooren, L. (2017). Testosterone therapy and body composition. https://doi.org/10.1016/j.jsxm.2017.01.002
Sánchez-Tapia, M., Tovar, A. R., & Torres, N. (2020). Bariatric surgery and gut microbiota. https://doi.org/10.1038/s41574-020-0346-1
Stute, P., Wildt, L., & Neubert, R. (2016). The impact of micronized progesterone on the endometrium and breast. https://doi.org/10.1016/j.maturitas.2016.03.012
Zimmerman, Y., Eijkemans, M. J. C., Coelingh Bennink, H. J. T., Blankenstein, M. A., & Fauser, B. C. J. M. (2014). The effect of combined oral contraceptives on SHBG. https://doi.org/10.1210/jc.2013-2396
The information herein on "Restoring Hormone Balance: A Patient-Centered Guide" is not intended to replace a one-on-one relationship with a qualified health care professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional.
Welcome to El Paso's Premier Wellness, Personal Injury Care Clinic & Wellness Blog, where Dr. Alex Jimenez, DC, FNP-C, a Multi-State board-certified Family Practice Nurse Practitioner (FNP-BC) and Chiropractor (DC), presents insights on how our multidisciplinary team is dedicated to holistic healing and personalized care. Our practice aligns with evidence-based treatment protocols inspired by integrative medicine principles, similar to those on this site and our family practice-based chiromed.comsite, and focuses on restoring health naturally for patients of all ages.
Our information scopeis multidisciplinary, focusing on musculoskeletal and physical medicine, wellness, contributing etiological viscerosomatic disturbances within clinical presentations, associated somato-visceral reflex clinical dynamics, subluxation complexes, sensitive health issues, and functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from various disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for musculoskeletal injuries or disorders.
Our videos, posts, topics, and insights address clinical matters and issues that are directly or indirectly related to our clinical scope of practice.
Our office has made a reasonable effort to provide supportive citations and has identified relevant research studies that support our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We understand that we cover matters that require an additional explanation of how they may assist in a particular care plan or treatment protocol; therefore, to discuss the subject matter above further, please feel free to ask Dr. Alex Jimenez, DC, APRN, FNP-BC, or contact us at 915-850-0900.
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico* Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-StateAdvanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-state Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified:1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 * Colorado License #: C-APN.0105610-C-NP, Verified: C-APN.0105610-C-NP New York License #: N25929, VerifiedN25929
DC: Doctor of Chiropractic APRNP: Advanced Practice Registered Nurse FNP-BC: Family Practice Specialization (Multi-State Board Certified) RN: Registered Nurse (Multi-State Compact License)
CFMP: Certified Functional Medicine Provider
MSN-FNP: Master of Science in Family Practice Medicine
MSACP: Master of Science in Advanced Clinical Practice
IFMCP: Institute of Functional Medicine
CCST: Certified Chiropractic Spinal Trauma
ATN: Advanced Translational Neutrogenomics
Memberships & Associations:
TCA: Texas Chiropractic Association: Member ID: 104311
AANP: American Association of Nurse Practitioners: Member ID: 2198960
ANA: American Nurse Association: Member ID: 06458222 (District TX01)
TNA: Texas Nurse Association: Member ID: 06458222